

---

# 10 Bioequivalence and Drug Product Assessment: In Vivo

*Barbara M. Davit and Dale P. Conner*

## CONTENTS

Introduction.....	220
Objectives of Bioequivalence Studies.....	220
History of Bioequivalence Evaluation in the United States.....	221
Drug Efficacy Study Implementation (DESI).....	221
Development of the FDA's Bioavailability/Bioequivalence Regulations.....	222
Creation of an Office of Technology Assessment (OTA).....	222
Publication of the 1977 Bioavailability and Bioequivalence Regulations.....	223
Availability of the Paper NDA Route for Duplicate Drug Products.....	223
1984 Hatch–Waxman Amendments.....	223
1992 Revisions to the FDA's Bioavailability/Bioequivalence Regulations.....	224
Early Days of the FDA's Bioequivalence Review Process.....	224
Two One-Sided Tests Procedure for Analyzing Bioequivalence Data.....	225
Logarithmic Transformation of Bioequivalence Data.....	225
Reference-Scaled Average Bioequivalence Approach.....	226
Role of $T_{\max}$ in Bioequivalence Analysis.....	228
Partial Auc.....	228
General Bioequivalence Study Design Recommendations.....	229
Number of Subjects; Single-Dose versus Steady-State Bioequivalence Studies....	230
Appropriate Drug Product Strength for Bioequivalence Studies.....	230
Fed Bioequivalence Studies.....	230
Study Population in Bioequivalence Studies.....	231
Types of Evidence to Establish Bioavailability and Bioequivalence.....	231
Bioequivalence Studies with Pharmacokinetic Endpoints.....	231
Bioequivalence Studies with Pharmacodynamic Endpoints.....	233
Bioequivalence Studies with Clinical Endpoints.....	234
Bioequivalence Studies with In Vitro Endpoints.....	235
Waivers of In Vivo Bioequivalence Testing Requirements for Oral Dosage Forms.....	236
Modified-Release Drug Products.....	236
Biopharmaceutics Classification System.....	236
Failed Bioequivalence Studies.....	237